+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029

  • ID: 5314299
  • Report
  • April 2021
  • Region: Global
  • 127 Pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AbbVie
  • B&A Therapeutics
  • GSK
  • Neuraly
  • Otsuka Pharmaceutical
  • Sunovion
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029

Summary

Parkinson's disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism-neurological disorders that lead to movement problems. While the exact cause of Parkinson's disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.

Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson's market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.

The publisher anticipates that the global PD market will experience significant growth during the forecast period; global sales are expected to increase from $3.5B in 2019 to $11.5B in 2029, at a Compound Annual Growth Rate (CAGR) of 12.6%. This growth will be driven by the launch of 17 late-stage pipeline products. The highest selling drugs are expected to be: Roche/Prothena's PRX-002 followed by Novo Nordisk's Victoza. PRX-002 is a mAb with disease-modifying properties. KOLs were optimistic about this drug and suggested it may revolutionize PD treatment. Also, the MOA of Victoza was highly regarded as a potential neuroprotective drug in addition to its established high safety profile.

Key Highlights

  • Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.
  • the publisher's anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.
  • Roche/Prothena's, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.
  • The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.
  • Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.

Key Questions Answered

  • What are the key PD treatments in 2019?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

  • Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2019 to 2029.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase IIb and Phase III development are profiled.
  • Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • B&A Therapeutics
  • GSK
  • Neuraly
  • Otsuka Pharmaceutical
  • Sunovion
1 Parkinson's Disease: Executive Summary
1.1 Parkinson's Market Expected to Grow Significantly, Driven by New Launches
1.2 High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market
1.3 Diverse Pipeline Agents Will Partially Address Key Unmet Needs
1.4 The Entry of Novel Biologics and Innovative Delivery Systems Will Shape the PD Market
1.5 What Do Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Mechanisms of Cell Death
3.2 Classification or Staging Systems

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for PD (2019-2029)
4.5.1 Diagnosed Prevalent Cases of PD
4.5.2 Sex-Specific Diagnosed Prevalent Cases of PD
4.5.3 Age-Specific Diagnosed Prevalent Cases of PD
4.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging
4.5.5 Diagnosed Prevalent Cases of PD by Type
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis

5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management

6 Competitive Assessment
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Effective Treatment of Motor Complications - Dyskinesia, Off-Episodes, Gait, and Balance Problems
7.3 New Therapies for Non-motor Complications - Psychosis and Dementia
7.4 Neuroprotective/Disease-Modifying Agents
7.5 Improved Drug Formulations

8 R&D Strategies
8.1 Overview
8.1.1 Development of Novel Targets ─ mAbs Targeting α-synuclein, and Gene Therapies
8.1.2 Innovative Drug Delivery Systems
8.1.3 Secondary Indications and Drug Repurposing
8.1.4 Clinical Trial Design
8.1.5 Reliable Biomarkers of Disease Progression
8.1.6 Genetic Studies Required to Learn About Genetic Subtypes of PD

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment

11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers

13 Appendix

List of Tables
  • Table 1: Parkinson's Disease: Key Metrics in the 7MM
  • Table 2: Modified HY Scale of PD Symptoms
  • Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2008
  • Table 4: Risk Factors and Comorbidities of PD
  • Table 5: Treatment Guidelines for PD
  • Table 6: Parkinson's Disease Market - Global Drivers and Barriers, 2019-2029
  • Table 7: Key Events Impacting Sales for Parkinson's Disease in the US, 2019-2029
  • Table 8: Parkinson's Disease Market - Drivers and Barriers in the US, 2019-2029
  • Table 9: Key Events Impacting Sales for Parkinson's Disease in the 5EU, 2019-2029
  • Table 10: Parkinson's Disease Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 11: Key Events Impacting Sales for PD in Japan, 2019-2029
  • Table 12: PD Market - Drivers and Barriers in Japan, 2019-2029
  • Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
  • Figure 1: Global Sales Forecast by Country for Parkinson's Disease in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in Parkinson's Disease During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson's Disease During the Forecast Period
  • Figure 4: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
  • Figure 7: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 8: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019
  • Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
  • Figure 10: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 11: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 12: Treatment Algorithm for Parkinson's Patients
  • Figure 13: Unmet Needs and Opportunities in PD
  • Figure 14: Pharmacokinetics of Levodopa
  • Figure 15: Overview of the Development Pipeline in Parkinson's Disease
  • Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period
  • Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson's Disease During the Forecast Period
  • Figure 18: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Sinemet
  • Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Requip
  • Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Nuplazid
  • Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Azilect
  • Figure 22: Analysis of the Company Portfolio Gap in Parkinson's Disease During the Forecast Period (2019-2029)
  • Figure 23: Global (7MM) Sales Forecast by Country for Parkinson's Disease in 2019 and 2029
  • Figure 24: Sales Forecast by Class for Parkinson's Disease in the US in 2019 and 2029
  • Figure 25: Sales Forecast by Class for Parkinson's Disease in the 5EU in 2019 and 2029
  • Figure 26: Sales Forecast by Class for PD in Japan in 2019 and 2029
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Teva
  • Roche
  • Prothena
  • Acorda Therapeutics
  • Voyager Therapeutics
  • Amneal Pharmaceuticals
  • UCB
  • AbbVie
  • Novartis
  • Orion Pharmaceuticals
  • Intec Pharma
  • NeuroDerm
  • Adamas Therapeutics
  • Acadia
  • Sunovion
  • Pharma Two B
  • Merck
  • GSK
  • Britannia Pharmaceuticals
  • Alkahest
  • Anavex Life Sciences
  • Novo Nordisk
  • Lundbeck
  • Supernus
  • Seelos Therapeutics
  • Living Cell Technologies
  • Prevail
  • Eli Lilly
  • Neuraly
  • US WorldMeds
  • Zambon
  • Eisai
  • Meiji Seika
  • Sanofi
  • Neurocrine Biosciences
  • Otsuka Pharmaceutical
  • Newron
  • Kyowa Kirin
  • Genzyme
  • Cerevel
  • Biogen
  • B&A Therapeutics
Note: Product cover images may vary from those shown